• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/19/21 5:10:50 PM ET
    $INFI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INFI alert in real time by email
    SC 13G 1 sc13g07422infi_02192021.htm THE SCHEDULE 13G

     UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

    (Amendment No. )1

     

    Infinity Pharmaceuticals, Inc.

     (Name of Issuer)

    Common Stock, $0.001 par value

     (Title of Class of Securities)

    45665G303

     (CUSIP Number)

    February 17, 2021

     (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

       ☐  Rule 13d-1(b)

       ☒  Rule 13d-1(c)

       ☐  Rule 13d-1(d)

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 45665G303

     

      1   NAME OF REPORTING PERSON  
             
            Biotechnology Value Fund, L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         4,448,421  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              4,448,421  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            4,448,421  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            5.3%  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    2

    CUSIP No. 45665G303

      1   NAME OF REPORTING PERSON  
             
            BVF I GP LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         4,448,421  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              4,448,421  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            4,448,421  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            5.3%  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    3

    CUSIP No. 45665G303

     

      1   NAME OF REPORTING PERSON  
             
            Biotechnology Value Fund II, L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         3,279,831  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              3,279,831  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            3,279,831  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            3.9%  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    4

    CUSIP No. 45665G303

     

      1   NAME OF REPORTING PERSON  
             
            BVF II GP LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         3,279,831  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              3,279,831  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            3,279,831  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            3.9%  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    5

    CUSIP No. 45665G303

     

      1   NAME OF REPORTING PERSON  
             
            Biotechnology Value Trading Fund OS LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Cayman Islands  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         534,847  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              534,847  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            534,847  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than 1%  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    6

    CUSIP No. 45665G303

     

      1   NAME OF REPORTING PERSON  
             
            BVF Partners OS Ltd.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Cayman Islands  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         534,847  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              534,847  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            534,847  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than 1%  
      12   TYPE OF REPORTING PERSON  
             
            CO  

      

    7

    CUSIP No. 45665G303

     

      1   NAME OF REPORTING PERSON  
             
            BVF GP HOLDINGS LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         7,728,252  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              7,728,252  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            7,728,252  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            9.2%  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    8

    CUSIP No. 45665G303

     

      1   NAME OF REPORTING PERSON  
             
            BVF Partners L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         8,383,645  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              8,383,645  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            8,383,645  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            9.96%  
      12   TYPE OF REPORTING PERSON  
             
            PN, IA  

      

    9

    CUSIP No. 45665G303

     

      1   NAME OF REPORTING PERSON  
             
            BVF Inc.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         8,383,645  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              8,383,645  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            8,383,645  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            9.96%  
      12   TYPE OF REPORTING PERSON  
             
            CO  

      

    10

    CUSIP No. 45665G303

     

      1   NAME OF REPORTING PERSON  
             
            Mark N. Lampert  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            United States  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0 shares  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         8,383,645  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0 shares  
        8   SHARED DISPOSITIVE POWER  
               
              8,383,645  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            8,383,645  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            9.96%  
      12   TYPE OF REPORTING PERSON  
             
            IN  

      

    11

    CUSIP No. 45665G303

    Item 1(a).Name of Issuer:

    Infinity Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”).

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    1100 Massachusetts Avenue, Floor 4

    Cambridge, Massachusetts 02138

     

    Item 2(a).Name of Person Filing
    Item 2(b).Address of Principal Business Office or, if None, Residence
    Item 2(c).Citizenship

     

    Biotechnology Value Fund, L.P. (“BVF”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    BVF I GP LLC (“BVF GP”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    Biotechnology Value Fund II, L.P. (“BVF2”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    BVF II GP LLC (“BVF2 GP”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    Biotechnology Value Trading Fund OS LP (“Trading Fund OS”)

    PO Box 309 Ugland House

    Grand Cayman, KY1-1104

    Cayman Islands

    Citizenship: Cayman Islands

     

    BVF Partners OS Ltd. (“Partners OS”)

    PO Box 309 Ugland House

    Grand Cayman, KY1-1104

    Cayman Islands

    Citizenship: Cayman Islands

     

    BVF GP Holdings LLC (“BVF GPH”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

    12

    CUSIP No. 45665G303

     

    BVF Partners L.P. (“Partners”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    BVF Inc.

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    Mark N. Lampert (“Mr. Lampert”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: United States

     

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, $0.001 par value (the “Shares”).

     

    Item 2(e).CUSIP Number:

     

    45665G303

     

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

        /x/ Not applicable.
           
      (a) / / Broker or dealer registered under Section 15 of the Exchange Act.
           
      (b) / / Bank as defined in Section 3(a)(6) of the Exchange Act.
           
      (c) / / Insurance company as defined in Section 3(a)(19) of the Exchange Act.
           
      (d) / / Investment company registered under Section 8 of the Investment Company Act.
           
      (e) / / An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
           
      (f) / / An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
           
      (g) / / A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
           
      (h) / / A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
           
      (i) / / A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
           
      (j) / / Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
           
      (k) / / Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    13

    CUSIP No. 45665G303

    Item 4.Ownership

     

    (a)Amount beneficially owned:

     

    As of the close of business on February 17, 2021, (i) BVF beneficially owned 4,448,421 Shares, (ii) BVF2 beneficially owned 3,279,831 Shares and (iii) Trading Fund OS beneficially owned 534,847 Shares.

     

    BVF GP, as the general partner of BVF, may be deemed to beneficially own the 4,448,421 Shares beneficially owned by BVF.

     

    BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 3,279,831 Shares beneficially owned by BVF2.

     

    Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 534,847 Shares beneficially owned by Trading Fund OS.

     

    BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 7,728,252 Shares beneficially owned in the aggregate by BVF and BVF2.

     

    Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 8,383,645 Shares beneficially owned in the aggregate by BVF, BVF2, Trading Fund OS, and a certain Partners managed account (the “Partners Managed Account”), including 120,546 Shares held in the Partners Managed Account.

     

    BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 8,383,645 Shares beneficially owned by Partners.

     

    Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 8,383,645 Shares beneficially owned by BVF Inc.

     

    The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2, Trading Fund OS, and the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

    14

    CUSIP No. 45665G303

     

    (b)Percent of class:

     

    The following percentages are based on 84,141,510 Shares outstanding, which is the total number of Shares outstanding as disclosed in the Issuer’s Prospectus Supplement on Form 424B5 filed with the Securities and Exchange Commission on February 12, 2021.

     

    As of the close of business on February 19, 2021, (i) BVF beneficially owned approximately 5.3% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 3.9% of the outstanding Shares, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 5.3% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own approximately 3.9% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own less than 1% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 9.2% of the outstanding Shares and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 9.96% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Account).

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote

     

    See Cover Pages Items 5-9.

     

    (ii)Shared power to vote or to direct the vote

     

    See Cover Pages Items 5-9.

     

    (iii)Sole power to dispose or to direct the disposition of

     

    See Cover Pages Items 5-9.

     

    (iv)Shared power to dispose or to direct the disposition of

     

    See Cover Pages Items 5-9.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    Not Applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    BVF GP, BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF. BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF2. Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by Trading Fund OS and the Partners Managed Account.

    15

    CUSIP No. 45665G303

     

    Item 7.Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    See Exhibit 99.1.

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10.Certifications.

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    16

    CUSIP No. 45665G303

     

    SIGNATURE

     

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: February 19, 2021

     

    BIOTECHNOLOGY VALUE FUND, L.P.   BIOTECHNOLOGY VALUE TRADING FUND OS LP
           
    By: BVF I GP LLC., its general partner   By: BVF Partners L.P., its investment manager
          By: BVF Inc., its general partner
    By:

    /s/ Mark N. Lampert

         
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            President
             
    BVF I GP LLC      
          BVF GP HOLDINGS LLC
    By: /s/ Mark N. Lampert    
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            Chief Executive Officer
             
    BIOTECHNOLOGY VALUE FUND II, L.P.    
          BVF PARTNERS L.P.
    By: BVF II GP LLC, its general partner    
          By: BVF Inc., its general partner
    By:

    /s/ Mark N. Lampert

         
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            President
             
    BVF II GP LLC      
          BVF INC.
    By: /s/ Mark N. Lampert    
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            President
             
    BVF PARTNERS OS LTD.      
          /s/ Mark N. Lampert
    By: BVF Partners L.P., its sole member   MARK N. LAMPERT
    By: BVF Inc., its general partner    
             
    By:

    /s/ Mark N. Lampert

         
      Mark N. Lampert      
      President      

       

    17

      

    Get the next $INFI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INFI

    DatePrice TargetRatingAnalyst
    10/18/2021$9.00Buy
    HC Wainwright & Co.
    8/2/2021$6.00Neutral → Overweight
    JP Morgan
    7/28/2021$4.00 → $14.00Equal-Weight → Overweight
    Wells Fargo
    7/7/2021$7.00Buy
    B. Riley Securities
    More analyst ratings

    $INFI
    SEC Filings

    See more
    • Infinity Pharmaceuticals Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Leadership Update

      8-K - INFINITY PHARMACEUTICALS, INC. (0001113148) (Filer)

      9/29/23 4:04:01 PM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Infinity Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - INFINITY PHARMACEUTICALS, INC. (0001113148) (Filer)

      9/13/23 8:11:15 AM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Infinity Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - INFINITY PHARMACEUTICALS, INC. (0001113148) (Filer)

      9/11/23 4:09:04 PM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INFI
    Financials

    Live finance-specific insights

    See more
    • MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates

      Combination will create a company with a diverse product development pipeline led by a planned new global Phase 2 clinical trial evaluating eganelisib in head and neck squamous cell carcinoma (HNSCC) Projected ~$100M cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months Companies to host conference call and webcast today at 8:00 a.m. ET MEI Pharma, Inc. (NASDAQ:MEIP) ("MEI"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno

      2/23/23 7:00:00 AM ET
      $INFI
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Infinity Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

      – MARIO-3 Update in Patients with 1L TNBC showing 52% increase in one-year progression free survival rate in ITT patient population compared to Impassion130 benchmark – – Business development discussions advancing with goal of announcing a partnership in Q1 2023 – – Cash runway into 2024 with $47.2 million in cash and cash equivalents at end of Q3 2022– – Investor conference call to be held today at 8:30 AM ET – Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its third quarter 2022 financial results, provi

      11/14/22 7:07:00 AM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Infinity Pharmaceuticals Announces the Date of Its Third Quarter 2022 Financial Results Conference Call and Webcast

      Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Monday, November 14, 2022, at 8:30 AM ET to report its financial results for the third quarter of 2022. To access the conference call, please register at https://register.vevent.com/register/BId44f86e6a2af42faadbb2844131346a8. Upon registering, each participant will be provided with call details and access codes. All participants are encouraged to join 10 minutes prior to the start time. A live webcast of the conference call can be accessed from the Events & Presentations page

      11/7/22 8:25:00 AM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INFI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on Infinity Pharmaceuticals with a new price target

      HC Wainwright & Co. initiated coverage of Infinity Pharmaceuticals with a rating of Buy and set a new price target of $9.00

      10/18/21 6:27:01 AM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Infinity Pharmaceuticals upgraded by JP Morgan with a new price target

      JP Morgan upgraded Infinity Pharmaceuticals from Neutral to Overweight and set a new price target of $6.00

      8/2/21 5:42:58 AM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Infinity Pharmaceuticals upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Infinity Pharmaceuticals from Equal-Weight to Overweight and set a new price target of $14.00 from $4.00 previously

      7/28/21 5:37:19 AM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INFI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Infinity Pharmaceuticals Announces Value Preservation and Maximization Plan

      Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced a series of actions designed to reduce the Company's burn rate and enhance our ability to maximize value of eganelisib, following the termination of its previously announced merger agreement with MEI Pharma, Inc. The Company continues to believe, based on the data generated to date, that eganelisib offers a near-term value creation opportunity that would be attractive to potential third-party acquirers. Infinity has advanced eganelisib toward the init

      7/25/23 4:05:00 PM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Infinity Pharmaceuticals Announces Termination of Merger Agreement with MEI Pharma

      Eganelisib Remains Primary Value Driver for Infinity Infinity to Explore Strategic Alternatives to Maximize Value for Stockholders Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, announced that it has terminated its previously announced merger agreement providing for the merger with MEI Pharma, Inc. ("MEI"). At a special meeting of MEI stockholders on July 23, 2023, MEI did not obtain MEI stockholder approval for the merger with Infinity, nor could MEI obtain approval for an adjournment of the special meeting. In the process o

      7/24/23 8:30:00 AM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction

      MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reminded shareholders to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity") in connection with the Company's special meeting on July 23, 2023. MEI issued the following statement: Our shareholders have the opportunity to shape the future of their MEI investment. By voting FOR the Infinity transaction today, you have the opportunity to participate in the upside potential of a combined company with: a diversified therapeutic pipeline; a team that brings clinical development and regulatory expertise; and the capabilities and resources to develop new oncology therapeutics for the benefi

      7/19/23 8:00:00 AM ET
      $INFI
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INFI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Infinity Pharmaceuticals Inc. (Amendment)

      SC 13G/A - INFINITY PHARMACEUTICALS, INC. (0001113148) (Subject)

      2/14/23 3:59:19 PM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Infinity Pharmaceuticals Inc. (Amendment)

      SC 13G/A - INFINITY PHARMACEUTICALS, INC. (0001113148) (Subject)

      2/9/23 11:22:21 AM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Infinity Pharmaceuticals Inc. (Amendment)

      SC 13G/A - INFINITY PHARMACEUTICALS, INC. (0001113148) (Subject)

      2/14/22 2:01:09 PM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INFI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Perkins Adelene Q converted options into 768,133 shares and sold $28,714 worth of shares (410,196 units at $0.07), increasing direct ownership by 44% to 1,175,291 units

      4 - INFINITY PHARMACEUTICALS, INC. (0001113148) (Issuer)

      9/12/23 6:20:24 PM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Peluso Stephane converted options into 50,000 shares, increasing direct ownership by 1,711% to 37,052 units to cover taxes

      4 - INFINITY PHARMACEUTICALS, INC. (0001113148) (Issuer)

      8/4/22 6:26:16 PM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Evnin Anthony B was granted 46,378 shares, increasing direct ownership by 27% to 215,403 units

      4 - INFINITY PHARMACEUTICALS, INC. (0001113148) (Issuer)

      6/16/22 9:29:24 PM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care